Glucose Transporters in Brain: In Health and in Alzheimer’s Disease
The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.
Abstract
Neurons need a continuous supply of glucose, the major source of energy for mammalian brain metabolism. The central nervous system is protected by three main physiological cell barriers. Cell membranes are impermeable for glucose, therefore glucose is transferred across the cell membranes by specific transport proteins: sodium-independent glucose transporters (GLUTs), encoded by SLC2 genes, and sodium-dependent glucose transporters (for example SGLTs), encoded by SLC5 genes. Human brain expresses 10 GLUT proteins and 10 proteins encoded by SLC5 genes. In patients with brain diseases, particularly Alzheimer's (AD) and Huntington's diseases, abnormalities in neuronal glucose metabolism have been showed. The levels of GLUT1 and GLUT3, the major brain glucose transporters, are decreased, especially in the cerebral cortex. Therefore, in AD, hypometabolism of glucose and deficits in energy are observed. Production of ATP from glucose metabolism in sporadic AD declines to 50% and the tendency to decline continues throughout the progression of the disease. This decrease is correlated with O-GlcAcetylation and tau hyperphosphorylation, as the compensatory mechanisms in AD are the utilization of endogenous brain substances and drastic increase in GLUT2 levels. The present review focuses on the changes in the expression of glucose transporters due to AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“researchers asserted that besides its role in glucose reabsorption, SGLT may exhibit other distinct functions in CNS.13–15”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [13]
Citations
Cites
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 2×
“Therefore, the concept of AD was proposed as “type 3 diabetes” [124].”
The SLC2 (GLUT) family of membrane transporters
Mueckler, M., & Thorens, B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.001 · Cited by 1,328
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Translating cell biology into therapeutic advances in Alzheimer's disease
Selkoe, D. J. (1999) · Nature · doi:10.1038/399a023 · Cited by 1,166 · cited 1×
“A (cid:2) 40 and A (cid:2) 42 are generated by the proteolytic cleavage of A (cid:2) PP with (cid:2) - and (cid:4) -secretases [132].”
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
Insulin receptors are widely distributed in the central nervous system of the rat
HAVRANKOVA, J., ROTH, J., & BROWNSTEIN, M. (1978) · Nature · doi:10.1038/272827a0 · Cited by 1,111
De Vivo, D. C., Trifiletti, R. R., Jacobson, R. I., Ronen, G. M., Behmand, R. A., & Harik, S. I. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109053251006 · Cited by 800
Research works printed but not linked: 2
- Welcome, 2011, Long-term disorders of cognitive functions in sober people who episodically use alcohol, role of functional hypoglycemia and insufficiency of gluconeogenesis, Vestnik Smolensk Med Acad, 3, 2
- Welcome, 2013, State of cognitive functions of student-medics with different relationship to alcohol use, 5
Cited by
Items 201–219 of 219
Felisatti, F. (2023) · theses.fr (ABES) · doi:10.70675/957c3e86z0eabz4d4bza536z8ed0d286cd98 · Cited by 3
Commitment to a Dementia-Free Society
Satoh, T. (2024) · Springer eBooks · doi:10.1007/978-3-031-54150-6_6
Hede, E., Burkhart, A., Aldana, B. I., Kohlmeier, K. A., Moos, T., & Thomsen, M. S. (2025) · Research Square · doi:10.21203/rs.3.rs-7374065/v1
The Effect of Dapagliflozin on Absence Epilepsy in WAG/Rij Rats
Aygün, H. (2025) · Archives of Epilepsy · doi:10.4274/archepilepsy.2025.25179
Khairunnisa, S., Maruyama, K., Miyazaki, S., Saito, I., Tomooka, K., Tanigawa, T., Eguchi, E., Shiba, T., Kooka, A., Fujimura, K., et al. (2025) · Dietetics · doi:10.3390/dietetics4040043
“DM can affect the progression of AD through insulin resistance [31], which has been shown to precipitate in reduced brain metabolism [32–34], amyloid-beta accumulation [35,36], tau protein hyper-phosphorylation [37,38], and increased oxidative burden [39,40].”
Candeias, E. M. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
[18F]FDG Revisited: A New Perspective on the Temporal Dynamics of Brain Glucose MetabolismPreprint
Hahn, A., Falb, P., Murgaš, M., Klug, S., Reed, M. B., Godbersen, G. M., de León, M. P., Milz, C., Hacker, M., Rujescu, D., et al. (2025) · Preprints.org · doi:10.20944/preprints202502.0892.v2 · Cited by 3
Neuronal GLUT3 alleviates hyperalgesia and neuroinflammation in chronic migraine mice
Zheng, J., Guo, Z., Ren, X., Liu, X., Wang, K., Lin, K., Wang, W., Yang, H., Wang, Y., Xu, Z., et al. (2026) · The Journal of Headache and Pain · doi:10.1186/s10194-026-02558-x
GHEORGHE, L. P. (2026) · Electronic Theses and Dissertations Repository (University of Pisa)
Advanced glycation end-products in the pathogenesis of Alzheimer’s disease: a review
Mazur, K., & Smoleń, A. (2026) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2026.0011
Gangwar, P., Yadav, B., Verma, H., Yadav, A., Rao, R., Kumari, K., Kumar, K., Kadhirvel, S., Dhiman, M., & Mantha, A. K. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154290
Hu, X., Yu, Y., Luo, H., Li, J., Zhang, X., Wang, G., Li, J., Li, J., Chen, H., & Qiu, Y. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00567-z
“On the other hand, AD brains exhibit decreased glucose transporter type 3 [29–31], which may compromise glucose delivery to neurons and then affect the PPP.”
Identification and Validation of the Nrf2/Slc2a1 Axis in Alzheimer’s Disease
Luo, Y., Deng, J., Loh, Y., Lu, H., Wang, N., Tang, C., & Zhang, B. (2026) · Genes · doi:10.3390/genes17091081
“Reduced GLUT1 expression has been consistently observed in the brains of patients with AD, leading to cerebral glucose hypometabolism and energy deficits, and may also contribute to tau hyperphosphorylation and A β deposition [28].”
Araripe, D. A., Iljin, M., Bange, H., Price, L., Liu, R., van der Es, D., Heitman, L. H., Peters, D. J. M., & van Westen, G. J. P. (2026) · SLAS DISCOVERY · doi:10.1016/j.slasd.2026.100338
Metabolic responses to O-GlcNAcase inhibition in AppNL-G-F mice
Ouyang, X., Tian, R., Benavides, G. A., Bell, M., Kramer, J. A., Qin, H., Smith, M. R., Jones, D. P., Go, Y., Darley-Usmar, V. M., et al. (2026) · Advances in Redox Research · doi:10.1016/j.arres.2026.100198
Utilization of L-type amino acid transporter 1 (LAT1) for targeted prodrug delivery
Huttunen, J. (2023) · UEF eRepo (University of Eastern Finland)
Metadata
- Authors
- Szablewski, L.
- Affiliations
- Medical University of Warsaw (PL)
- Corresponding author
- Szablewski, Leszek
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2016-12-20
- Volume
- 55
- Issue
- 4
- Pages
- 1307-1320
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2554650037
- Cited by
- 211
- References
- 161
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 25 · 2023: 20 · 2022: 30 · 2021: 32 · 2020: 35 · 2019: 19 · 2018: 6 · 2017: 6
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- glucose transporters, Alzheimer's disease
- MeSH terms
- Acetylation, Alzheimer Disease, Animals, Brain, Gene Expression Regulation, Humans, Phosphorylation, tau Proteins, N-Acetylglucosaminyltransferases, Glucose Transport Proteins, Facilitative
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.